New study tests antacid for Post-PPI acid rebound relief

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Eligibility Criteria: Adult female or male subjects aged ≥ 18 * Subjects who have discontinued daily PPI therapy (≥ 8 weeks of therapy) for which there is no current indication according to guidelines and approval status, e.g. * irritable bowel syndrome * subjects who receive Non-Steroidal Anti-Inflammatory drug (NSAID) treatment with no warning signals\* regarding ulcers * polymedication\*\* with no warning signals\* or side effects regarding ulcers * unclarified upper abdominal discomfort * mild forms of GERD; like Non-Erosive Reflux Disease (NERD), Los Angeles (LA) grade A/B esophagitis * Suffer from acid-rebound due to a discontinuation of a non/no longer indicated long-term PPI therapy (≥ 8 weeks of therapy) * No endoscopically diagnosed GERD\*\*\* * No indication for a PPI-therapy according to guidelines. Examples for guideline recommendations for a PPI-therapy: * moderate - severe forms of reflux esophagitis * gastric ulcer, duodenal ulcer * Helicobacter pylori eradication * moderate/severe forms of GERD - Los Angeles (LA) grade C/D esophagitis * Zollinger-Ellison-Syndrome No Talcid® contraindications or warnings as: * pregnancy and lactation * severe renal impairment * hypophosphatemia * existing myasthenia gravis * impaired renal function * Alzheimer's disease or other forms of dementia * patients under low-phosphate diet * hypersensitivity to the ingredients of Talcid® * Subjects who voluntarily agree to use Talcid® Chewable Tablets for relief of acid-related symptoms due to acid-rebound * Decision to initiate on-demand treatment of acid-related symptoms due to acid-rebound with Talcid® was made as per investigator's routine recommendation practice and by the subject * Subject purchases Talcid® for her/his own use * Signed informed consent * No participation in an investigational program with interventions outside of routine clinical practice * No contraindications according to the local marketing authorization \* Warning signals: * Age \> 60 (with one additional warning signal) * Previous history or family history of ulcers * Helicobacter pylori positive status \*\* Polymedication: defined as at least five medicinal products at the same time for a continuous therapy \*\*\* Endoscopy: LA grade C/ D esophagitis, Barrett esophagus, peptic stricture; pH- Impedance measurement: acid exposure \> 6% Exclusion Criteria: not applicable